Printer Friendly

MEDTRONIC REPORTS REGULATORY ACTION ON TRANSVENE LEAD SYSTEM

 MINNEAPOLIS, Sept. 29 /PRNewswire/ -- Medtronic, Inc. (NYSE: MDT) said today that it had received an "approvable" letter from the U.S. Food and Drug Administration (FDA) for the Medtronic Transvene(R) lead system. This is the last step in the regulatory process before final FDA clearance for marketing in the United States.
 William W. George, president and chief executive officer, said, "Medtronic is delighted to reach this milestone so soon after receiving the favorable recommendation of an FDA advisory panel in early August."
 Transvenous leads are designed to be maneuvered through the vascular system to deliver electrical impulses from the Medtronic PCD(R), an implantable device that delivers tiered therapy for hearts that beat abnormally fast. The less-invasive, more cost-effective Transvene system has been marketed in Europe since 1991. Medtronic lead systems currently available commercially in the United States are surgically affixed to the outside surface of the heart.
 Medtronic, Inc., headquartered in Minneapolis, is the world's leading therapeutic medical device company.
 -0- 9/29/93
 /CONTACT: Dale Beumer, investor relations, 612-574-3038; or Dick Reid, public relations, 612-574-3052/
 (MDT)


CO: Medtronic, Inc. ST: Minnesota IN: MTC SU:

KH-DS -- MN010 -- 6906 09/29/93 15:05 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 29, 1993
Words:196
Previous Article:NEXT DC-X FLIGHT TEST SCHEDULED ON THURSDAY
Next Article:UNITED AIRLINES CHAIRMAN SAYS OSAKA POISED FOR GLOBAL AIR TRANSPORTATION SUCCESS IF GOVERNMENT OFFICIALS DROP CALLS FOR MANAGED TRADE
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters